Charles River and CHDI Foundation Extend Huntington’s Disease Collaboration
Charles River and CHDI Foundation recently announced a five-year extension of their ongoing collaboration. The organizations began working together in 2005 on drug discovery and development for Huntington’s disease (HD), a genetic neurological disease that causes the progressive dysfunction of nerve cells in the brain. The extension will allow more flexible activity across the different Charles River platforms and entail greater integration into CHDI’s programs.
Over their 14-year collaboration, Charles River has established and validated tools and methodologies within expert teams to support CHDI’s mission of developing novel therapeutics that will substantially improve the lives of those affected by HD. Birgit Girshick, Corporate Executive Vice President, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services at Charles River, commented, “Our longstanding partnership with CHDI is built on our mutual commitment to developing novel therapies for Huntington’s disease. As an organization, our work with CHDI has led to a much larger commitment to support the HD research community, through investments in methodologies, tools, and personnel dedicated to this rare disease.”
Together, Charles River and CHDI have identified novel potential drug targets, bred and validated translational research animal models, run large screens and generated proof-of-concept molecules, and evaluated the potential efficacy of both small molecule and biologic candidates in preclinical models of HD. These cutting-edge approaches have resulted in over one hundred co-authored posters and dozens of peer-reviewed papers. Additionally, the expertise developed throughout this partnership has helped more broadly facilitate increased HD research within the larger drug discovery and development community.